An Open Label, Phase 2 Trial of Immunotherapy With Sipuleucel-T (Provenge®) as Neoadjuvant Treatment in Men With Localized Prostate Cancer
This is a single center, open label, Phase 2 study. Subjects will be treated with 3
infusions of sipuleucel-T prior to a scheduled radical prostatectomy (RP) surgery. To
assess the immune response following treatment with sipuleucel-T, tissue from the
prostatectomy specimen will be compared with tissue from the core biopsy specimen obtained
prior to treatment with sipuleucel T. Following RP, subjects will be randomized to receive
either a booster infusion of sipuleucel T or no further treatment with sipuleucel-T (i.e.,
booster: no booster).
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the immune response within prostate tissue following neoadjuvant treatment with sipuleucel-T.
baseline and at prostatectomy
No
Robert Sims, MD
Study Director
Dendreon
United States: Food and Drug Administration
P07-1
NCT00715104
July 2008
December 2013
Name | Location |
---|---|
Virginia Mason Medical Center | Seattle, Washington 98111 |
UCSF Comprehensive Cancer Center | San Francisco, California 94115 |
Seattle Cancer Care Alliance | Seattle, Washington 98109 |
Oregon Health & Science University | Portland, Oregon 97201 |
University of Utah School of Medicine | Salt Lake City, Utah 84132 |
USC / Norris Comprehensive Cancer Center | Los Angeles, California 90033 |
Kaiser Permanente Portland | Portland, Oregon 97227 |